The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
|Videos|March 23, 2016
New Trends in Afib Management
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses new trends pharmacists should know about atrial fibrillation management.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses new trends pharmacists should know about atrial fibrillation management.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Related to this article
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
3
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
4
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
5